CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is positioned for significant growth, evidenced by a fourfold increase in T-cell expansion that indicates enhanced efficacy at higher dosing levels, as well as a projected acceleration in sales due to a sizable patient funnel anticipated for 2026. Furthermore, the company's CTX320 candidate has achieved up to 50% editing efficiency, with the potential for even higher efficacy through follow-on CTX321, reflecting ongoing innovation and improvement in their gene editing programs. The optimistic outlook is further bolstered by strong demand projections for Casgevy and potential expansion into multiple high-total addressable market (TAM) indications, which could drive substantial revenue growth moving forward.

CRISPR Therapeutics's outlook is negatively impacted by the significant regulatory risks associated with its product development; failure to achieve regulatory approval for its therapeutics could lead to downward revisions in risk-adjusted projections and target price. Furthermore, the company's bear case scenario suggests that if sales of its approved drug, Casgevy, do not accelerate and earlier-stage programs are discontinued, there could be a substantial 30% downside to its base case valuation. Lastly, the anticipated revenue growth from Casgevy is now projected to be slower, with a reduction in expected market penetration from 15% to 10% of eligible patients by 2035, indicating potential challenges in revenue generation.